Overview

Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis

Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This study aims to compare the incidence of graft-versus-host disease (GVHD) in haploidentical hematopoietic stem cell transplant recipients who receive varying doses of anti-T lymphocyte globulin (ATLG) for GVHD prophylaxis. Our primary objective is to determine the optimal dose of ATLG for preventing acute GVHD (aGVHD). Additionally, we plan to evaluate the impact of different doses of ATLG on post-transplant viral infections and other clinical outcomes.
Phase:
PHASE3
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China